AXSM vs. BHVN, SMMT, CRNX, RARE, PBH, INSM, HCM, XENE, ALKS, and PRGO
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Biohaven (BHVN), Summit Therapeutics (SMMT), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), Prestige Consumer Healthcare (PBH), Insmed (INSM), HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Axsome Therapeutics (NASDAQ:AXSM) and Biohaven (NYSE:BHVN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 24.5% of Axsome Therapeutics shares are owned by insiders. Comparatively, 16.0% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Axsome Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.
Axsome Therapeutics received 52 more outperform votes than Biohaven when rated by MarketBeat users. Likewise, 68.67% of users gave Axsome Therapeutics an outperform vote while only 65.43% of users gave Biohaven an outperform vote.
In the previous week, Axsome Therapeutics had 41 more articles in the media than Biohaven. MarketBeat recorded 51 mentions for Axsome Therapeutics and 10 mentions for Biohaven. Axsome Therapeutics' average media sentiment score of 0.05 beat Biohaven's score of -0.55 indicating that Axsome Therapeutics is being referred to more favorably in the media.
Biohaven has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -118.07%. Axsome Therapeutics' return on equity of -87.17% beat Biohaven's return on equity.
Axsome Therapeutics presently has a consensus target price of $121.92, indicating a potential upside of 61.18%. Biohaven has a consensus target price of $51.63, indicating a potential upside of 52.83%. Given Axsome Therapeutics' higher possible upside, equities analysts plainly believe Axsome Therapeutics is more favorable than Biohaven.
Axsome Therapeutics has higher earnings, but lower revenue than Biohaven. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Summary
Axsome Therapeutics beats Biohaven on 12 of the 18 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
